Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianghua Tu

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Scientific Reports|December 8, 2019
The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesisJianghua Tu, Soohyun Park, Wangsheng Yu, et al.
Science Signaling|December 2, 2020
Unlike LGR4, LGR5 potentiates Wnt-β-catenin signaling without sequestering E3 ligasesSoohyun Park, Ling Wu, Jianghua Tu, et al.
Scientific Reports|July 4, 2023
LGR4 and LGR5 form distinct homodimers that only LGR4 complexes with RNF43/ZNRF3 to provide high affinity binding of R-spondin ligandsYukimatsu Toh, Ling Wu, Soohyun Park, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
RSPO2-based peptibodies conjugated with pyrrolobenzodiazepine dimer or camptothecin analogs demonstrate potent anti-tumor activity by targeting the three receptors LGR4/5/6Yukimatsu Toh, Jianghua Tu, Ling Wu, et al.
Journal of Medicinal Chemistry|August 18, 2021
Drug Conjugates of Antagonistic R-Spondin 4 Mutant for Simultaneous Targeting of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors 4/5/6 for Cancer TreatmentJie Cui, Yukimatsu Toh, Soohyun Park, et al.
Pharmaceutics|July 27, 2024
Antitumor Activity of a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting LGR5 in Preclinical Models of NeuroblastomaJianghua Tu, Yukimatsu Toh, Adela M Aldana, et al.
Journal of Medicinal Chemistry|April 9, 2026
RSPO2-Based Peptibodies Conjugated with Pyrrolobenzodiazepine Dimer or Camptothecin Analogs Demonstrate Potent Antitumor Activity by Targeting the Three Receptors LGR4/5/6 in Colorectal Cancer and NeuroblastomaYukimatsu Toh, Jianghua Tu, Ling Wu, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerYukimatsu Toh, Ling Wu, Jianghua Tu, et al.
British Journal of Cancer|August 18, 2025
Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerYukimatsu Toh, Ling Wu, Jianghua Tu, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Loss of ZNRF3/RNF43 Unleashes EGFR in CancerFei Yue, Amy T Ku, Payton D Stevens, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Scientific Reports|December 8, 2019
The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesisJianghua Tu, Soohyun Park, Wangsheng Yu, et al.
Science Signaling|December 2, 2020
Unlike LGR4, LGR5 potentiates Wnt-β-catenin signaling without sequestering E3 ligasesSoohyun Park, Ling Wu, Jianghua Tu, et al.
Scientific Reports|July 4, 2023
LGR4 and LGR5 form distinct homodimers that only LGR4 complexes with RNF43/ZNRF3 to provide high affinity binding of R-spondin ligandsYukimatsu Toh, Ling Wu, Soohyun Park, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
RSPO2-based peptibodies conjugated with pyrrolobenzodiazepine dimer or camptothecin analogs demonstrate potent anti-tumor activity by targeting the three receptors LGR4/5/6Yukimatsu Toh, Jianghua Tu, Ling Wu, et al.
Journal of Medicinal Chemistry|August 18, 2021
Drug Conjugates of Antagonistic R-Spondin 4 Mutant for Simultaneous Targeting of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors 4/5/6 for Cancer TreatmentJie Cui, Yukimatsu Toh, Soohyun Park, et al.
Pharmaceutics|July 27, 2024
Antitumor Activity of a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting LGR5 in Preclinical Models of NeuroblastomaJianghua Tu, Yukimatsu Toh, Adela M Aldana, et al.
Journal of Medicinal Chemistry|April 9, 2026
RSPO2-Based Peptibodies Conjugated with Pyrrolobenzodiazepine Dimer or Camptothecin Analogs Demonstrate Potent Antitumor Activity by Targeting the Three Receptors LGR4/5/6 in Colorectal Cancer and NeuroblastomaYukimatsu Toh, Jianghua Tu, Ling Wu, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerYukimatsu Toh, Ling Wu, Jianghua Tu, et al.
British Journal of Cancer|August 18, 2025
Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerYukimatsu Toh, Ling Wu, Jianghua Tu, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Loss of ZNRF3/RNF43 Unleashes EGFR in CancerFei Yue, Amy T Ku, Payton D Stevens, et al.
Pageof 2